Intraarterial microdosing: A novel drug development approach, proof-of-concept PET study in rats

Journal of Nuclear Medicine

Volumn 56, Issue 11, 2015, Pages 1793-1799

  Burt, Tal ^a   Rouse, Douglas C ^a   Lee, Kihak ^b   Wu, Huali ^a   Layton, Anita T ^a   Hawk, Thomas C ^a   Weitzel, Douglas H ^a   Chin, Bennett B ^a   Cohen Wolkowiez, Michael ^a   Chow, Shein Chung ^a   Noveck, Robert J ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SIEMENS CORPORATE RESEARCH   (United States)

Author keywords

Drug development; Exploratory investigational new drug (eIND); Intra arterial; Microdosing; PET imaging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; FEMORAL ARTERY; GASTROCNEMIUS MUSCLE; GLUCOSE BLOOD LEVEL; IMAGE ANALYSIS; INSULIN BLOOD LEVEL; INTRAARTERIAL DRUG ADMINISTRATION; INTRAARTERIAL MICRODOSING; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NONHUMAN; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RAT; SKELETAL MUSCLE; SPINOTRAPEZIUS MUSCLE; ALGORITHM; ANIMAL; BLOOD; COMPUTER ASSISTED DIAGNOSIS; COMPUTER SIMULATION; METABOLISM; PROCEDURES; STATISTICAL MODEL;

ALGORITHMS; ANIMALS; BLOOD GLUCOSE; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; FLUORODEOXYGLUCOSE F18; HYPOGLYCEMIC AGENTS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INJECTIONS, INTRA-ARTERIAL; INSULIN; MALE; MODELS, STATISTICAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS;

EID: 84946561101     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.160986     Document Type: Article

References (32)

1. Getz KA, Wenger J, Campo RA, Seguine ES, Kaitin KI. Assessing the impact of protocol design changes on clinical trial performance. Am J Ther. 2008;15: 450-457.
2. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87:272-277.
3. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov. 2011;10:428-438.
4. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9: 203-214.
5. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. Food and Drug Administration website. http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm. Accessed September 11, 2015.
6. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8:959-968.
7. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11: 191-200.
8. Coller BS, Califf RM. Traversing the Valley of Death: a guide to assessing prospects for translational success. Sci Transl Med. 2009;1:10cm9.
9. Henderson VC, Kimmelman J, Fergusson D, Grimshaw JM, Hackam DG. Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS Med. 2013;10:e1001489.
10. Rowland M. Microdosing and the 3Rs. National Library of Australia website. http://trove.nla.gov.au/version/166532644.2006. Accessed September 11, 2015.
11. van der Worp HB, Howells DW, Sena ES, et al. Can animal models of disease reliably inform human studies? PLoS Med. 2010;7:e1000245.
12. International Conference on Harmonization. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2). In: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Geneva, Switzerland: ICH Secretariat; 2009:8-16.
13. Lappin G, Noveck R, Burt T. Microdosing and drug development: past, present and future. Expert Opin Drug Metab Toxicol. 2013;9:817-834.
14. Bergström M, Grahnen A, Langstrom B. Positron emission tomography micro-dosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol. 2003;59:357-366.
15. Lappin G, Garner RC. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov. 2003;2: 233-240.
16. Guidance for industry, investigators, and reviewers exploratory IND studies. Food and Drug Administration website. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078933.pdf. Accessed September 11, 2015.
17. Collins FS. Reengineering translational science: the time is right. Sci Transl Med. 2011;3:90cm17.
18. Bertino JS Jr, Greenberg HE, Reed MD. American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process. J Clin Pharmacol. 2007;47:418-422.
19. Wilding IR, Bell JA. Improved early clinical development through human micro-dosing studies. Drug Discov Today. 2005;10:890-894.
20. Yamane N, Igarashi A, Kusama M, Maeda K, Ikeda T, Sugiyama Y. Cost-effectiveness analysis of microdose clinical trials in drug development. Drug Metab Pharmacokinet. 2013;28:187-195.
21. Zimmer L. Can positron emission tomography facilitate paediatric drug development? Fundam Clin Pharmacol. 2008;22:595-598.
22. Suckow C, Kuntner C, Chow P, Silverman R, Chatziioannou A, Stout D. Multi-modality rodent imaging chambers for use under barrier conditions with gas anesthesia. Mol Imaging Biol. 2009;11:100-106.
23. Chow PL, Rannou FR, Chatziioannou AF. Attenuation correction for small animal PET tomographs. Phys Med Biol. 2005;50:1837-1850.
24. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology. 1999;213:521-525.
25. Byrnes KR, Wilson CM, Brabazon F, et al. FDG-PET imaging in mild traumatic brain injury: a critical review. Front Neuroenergetics. 2014;5:1-24.
26. Wu HM, Sui G, Lee CC, et al. In vivo quantitation of glucose metabolism in mice using small-animal PET and a microfluidic device. J Nucl Med. 2007;48: 837-845.
27. Morgan P, Van Der Graaf PH, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today. 2012;17: 419-424.
28. Kaddurah-Daouk R, Weinshilboum RM. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther. 2014;95:154-167.
29. Croft M, Keely B, Morris I, Tann L, Lappin G. Predicting drug candidate victims of drug-drug interactions, using microdosing. Clin Pharmacokinet. 2012;51:237-246.
30. Wagner CC, Langer O. Approaches using molecular imaging technology: use of PET in clinical microdose studies. Adv Drug Deliv Rev. 2011;63: 539-546.
31. Sugiyama Y, Yamashita S. Impact of microdosing clinical study: why necessary and how useful? Adv Drug Deliv Rev. 2011;63:494-502.
32. Maeda K, Sugiyama Y. Novel strategies for microdose studies using non-radiolabeled compounds. Adv Drug Deliv Rev. 2011;63:532-538.